By using this site, you agree to the Privacy Policy and Terms of Use.
Accept
Medical Information, Documents, News - TheMediTary.Com Logo Medical Information, Documents, News - TheMediTary.Com Logo

TheMediTary.Com

Medical Information, Documents, News - TheMediTary.Com

  • Home
  • News
  • Drugs
  • Drugs A-Z
  • Medical Answers
  • About Us
  • Contact
Medical Information, Documents, News - TheMediTary.Com Logo Medical Information, Documents, News - TheMediTary.Com Logo
Search Drugs
  • Drugs
    • Latest Drugs
    • Drugs A-Z
    • Medical Answers
  • News
    • FDA Alerts
    • Medical News
    • Health
    • Consumer Updates
    • Children's Health
  • More TheMediTary.Com
    • About Us
    • Contact
Follow US
Home > Drugs > Erythromycin (eent) (monograph)
Drugs

Erythromycin (eent) (monograph)

https://themeditary.com/drug/erythromycin-eent-monograph-8002.html
Medically Reviewed by Glamora Samuels, MD TheMediTary.Com | Reviewed: Aug 16, 2023  Additional Content by TheMediTary.Com

Generic name: medically reviewed

Availability: Prescription only

Pregnancy & Lactation: Risk data not available

Brand names: Erythromycin ophthalmic, Eyemycin

Contents
Uses Warnings Before Taking Dosage Side effects Interactions

What is Erythromycin (eent) (monograph)?

Introduction

Antibacterial; macrolide antibiotic.

Uses for Erythromycin (EENT)

Bacterial Ophthalmic Infections

Topical treatment of superficial infections of the eye involving the conjunctiva and/or cornea caused by susceptible bacteria.

Mild, acute bacterial conjunctivitis often resolves spontaneously without anti-infective treatment. Although topical ophthalmic anti-infectives may shorten time to resolution and reduce severity and risk of complications, avoid indiscriminate use of topical anti-infectives.

Treatment of acute bacterial conjunctivitis generally is empiric; use of a broad-spectrum topical ophthalmic antibacterial usually recommended. In vitro staining and/or cultures of conjunctival material indicated in diagnosis and management of all cases of suspected infectious conjunctivitis in neonates, all cases of suspected gonococcal or chlamydial conjunctivitis, and may be indicated in management of recurrent, severe, or chronic purulent conjunctivitis or when acute conjunctivitis does not respond to initial empiric topical treatment.

Bacterial conjunctivitis caused by Neisseria gonorrhoeae requires treatment with systemic anti-infectives (e.g., IM or IV ceftriaxone) with or without topical anti-infectives. Topical anti-infectives alone are inadequate for treatment of ophthalmia neonatorum caused by N. gonorrhoeae; some experts state that adjunctive use of topical anti-infectives unnecessary when appropriate systemic anti-infectives used.

Chlamydial Ophthalmic Infections

Has been used topically in the treatment of conjunctivitis secondary to trachoma caused by Chlamydia trachomatis† [off-label]; however, systemic anti-infectives (usually oral azithromycin) are recommended for treatment of ocular trachoma.

Systemic anti-infectives (e.g., oral azithromycin, doxycycline, or erythromycin) are necessary for treatment of chlamydial conjunctivitis, including chlamydial ophthalmia neonatorum. Experts state that topical anti-infectives alone are inadequate for treatment of chlamydial ophthalmic infections and are unnecessary when appropriate systemic anti-infectives used.

Has been used for topical prophylaxis of ophthalmia neonatorum caused by C. trachomatis. However, efficacy of topical prophylaxis for prevention of chlamydial neonatal conjunctivitis not established. Experts state that erythromycin used for topical prophylaxis of gonococcal ophthalmia neonatorum will not prevent chlamydial ophthalmia neonatorum.

Prophylaxis of Gonococcal Ophthalmia Neonatorum

Topical prophylaxis of ophthalmia neonatorum caused by N. gonorrhoeae. Efficacy for prevention of ophthalmia neonatorum caused by penicillinase-producing N. gonorrhoeae not established.

CDC and AAP recommend topical erythromycin prophylaxis in all neonates as soon as possible after birth (regardless of whether they are delivered vaginally or by cesarean section); such prophylaxis required by law in most states. Although silver nitrate and tetracycline have been used in the past for topical prophylaxis of gonococcal ophthalmia neonatorum, ophthalmic preparations of these drugs no longer commercially available in the US.

If erythromycin ophthalmic ointment not available, CDC recommends systemic prophylaxis with a single dose of ceftriaxone (IM or IV) for all neonates at risk for exposure to N. gonorrhoeae (especially those born to women who are at risk for gonococcal infection or received no prenatal care).

Infants born to women with untreated gonorrhea are at high risk of infection; CDC and AAP recommend that such neonates receive systemic prophylaxis with a single dose of ceftriaxone (IM or IV) instead of topical erythromycin prophylaxis.

Erythromycin (EENT) Dosage and Administration

Administration

Ophthalmic Administration

Apply 0.5% ophthalmic ointment topically to the eye.

For topical ophthalmic use only.

Avoid contaminating tip of ointment tube with material from eye, fingers, or other source.

When used for prophylaxis of gonococcal ophthalmia neonatorum, place specified amount of ointment into each of neonate’s lower conjunctival sacs and massage gently to spread ointment; after 1 minute, wipe away excess ointment with sterile cotton. Do not flush ointment from the eye following application. Use a new tube or single-use container of ointment for each neonate.

Dosage

Pediatric Patients

Bacterial Ophthalmic Infections
Ophthalmic

Apply 1-cm ribbon of 0.5% ointment to the affected eye(s) up to 6 times daily. For empiric treatment of acute bacterial conjunctivitis, experts recommend application 4 times daily for 1 week.

Prophylaxis of Gonococcal Ophthalmia Neonatorum
Ophthalmic

Place 1-cm ribbon of 0.5% ointment into lower conjunctival sac of both eyes.

Administer as soon as possible (within 1 hour) after birth. Efficacy unlikely to be affected if topical prophylaxis delayed for up to 1 hour after delivery (e.g., to facilitate parent-infant bonding); efficacy of prophylaxis administered after a longer delay not studied.

Adults

Bacterial Ophthalmic Infections
Ophthalmic

Apply 1-cm ribbon of 0.5% ointment to the affected eye(s) up to 6 times daily. For empiric treatment of acute bacterial conjunctivitis, experts recommend application 4 times daily for 1 week.

Warnings

Contraindications

  • Hypersensitivity to erythromycin.

Warnings/Precautions

Sensitivity Reactions

Hypersensitivity

Possible sensitivity reactions.

General Precautions

Superinfection

Prolonged use may result in overgrowth of nonsusceptible organisms, including fungi.

If superinfection occurs, discontinue and institute appropriate therapy.

Specific Populations

Pregnancy

Data not available regarding use in pregnant women. Use only if clearly needed.

Lactation

Use with caution in nursing women.

Pediatric Use

See Uses.

Geriatric Use

No overall differences in safety or efficacy compared with younger patients.

Common Adverse Effects

Minor ocular irritation, redness, hypersensitivity.

How should I use Erythromycin (eent) (monograph)

Administration

Ophthalmic Administration

Apply 0.5% ophthalmic ointment topically to the eye.

For topical ophthalmic use only.

Avoid contaminating tip of ointment tube with material from eye, fingers, or other source.

When used for prophylaxis of gonococcal ophthalmia neonatorum, place specified amount of ointment into each of neonate’s lower conjunctival sacs and massage gently to spread ointment; after 1 minute, wipe away excess ointment with sterile cotton. Do not flush ointment from the eye following application. Use a new tube or single-use container of ointment for each neonate.

Dosage

Pediatric Patients

Bacterial Ophthalmic Infections
Ophthalmic

Apply 1-cm ribbon of 0.5% ointment to the affected eye(s) up to 6 times daily. For empiric treatment of acute bacterial conjunctivitis, experts recommend application 4 times daily for 1 week.

Prophylaxis of Gonococcal Ophthalmia Neonatorum
Ophthalmic

Place 1-cm ribbon of 0.5% ointment into lower conjunctival sac of both eyes.

Administer as soon as possible (within 1 hour) after birth. Efficacy unlikely to be affected if topical prophylaxis delayed for up to 1 hour after delivery (e.g., to facilitate parent-infant bonding); efficacy of prophylaxis administered after a longer delay not studied.

Adults

Bacterial Ophthalmic Infections
Ophthalmic

Apply 1-cm ribbon of 0.5% ointment to the affected eye(s) up to 6 times daily. For empiric treatment of acute bacterial conjunctivitis, experts recommend application 4 times daily for 1 week.

More about Erythromycin (eent) (monograph) (Medically reviewed)

Erythromycin (eent) (monograph) Side Effects
Erythromycin Ophthalmic Ointment Prescribing Information
Drug images
Side effects
Breastfeeding Warnings
Drug class: Drugs

Related treatment guides

Conjunctivitis, Bacterial
Share this Article
Contents
Uses Warnings Before Taking Dosage Side effects Interactions
Related Drugs
Fidanacogene Elaparvovec
Cerave Anti-Itch
Centrum Adult
Crovalimab
Cyltezo Prefilled Syringe
Zepbound Pen
Mylanta One
Uretron Ds
Medihoney Wound And Burn Dressing
Lidotrode

Other drugs

Name Drug Class Updated
Fidanacogene Elaparvovec Drugs 03-Oct-2024
Cerave Anti-Itch Drugs 02-Oct-2024
Centrum Adult Drugs 02-Oct-2024
Crovalimab Drugs 02-Oct-2024
Cyltezo Prefilled Syringe Drugs 01-Oct-2024
Zepbound Pen Drugs 30-Sep-2024
Mylanta One Drugs 27-Sep-2024
Uretron Ds Drugs 27-Sep-2024
Medihoney Wound And Burn Dressing Drugs 26-Sep-2024
Lidotrode Drugs 26-Sep-2024
Libervant Drugs 26-Sep-2024
Moderna Covid-19 Drugs 25-Sep-2024
Beqvez Drugs 24-Sep-2024
Beqvez Drugs 24-Sep-2024
Beqvez Drugs 24-Sep-2024

Categories

  • FDA Alerts
  • Medical News
  • Health
  • Consumer Updates
  • Children's Health

About US

Welcome to TheMediTary.Com

Our website provides reliable and up-to-date information on various medical topics. We empower individuals to take charge of their health by simplifying complex medical jargon and providing practical tips and advice. We prioritize the privacy and confidentiality of our users and welcome feedback to improve our services.

Website use data of FDA and other sources

DMCA.com Protection Status Truste Protection Status Trust Mark Protection Status
HONcode logo We comply with the HONcode standard for trustworthy health information.
Quick Link
  • About Us
  • Contact Us
  • Editorial Policy
  • Privacy Policy
  • Accessibility Policy
  • Terms & Conditions
  • Disclaimer
  • DMCA
  • Do Not Sell My Personal Information
  • Sitemap
  • Care Notes
  • Health Guide
  • Professional
Drugs
  • New Drugs
  • Medical Answers
  • Drugs A-Z
  • Drug Classes
  • Drug Dosage
  • Pill Identifier
  • Consumer Infor
  • Side Effects
  • Inactive Ingredients
  • Pregnancy Warnings
  • Patient Tips
  • Treatments
News
  • Latest News
  • FDA Alerts
  • Medical News
  • Health
  • Consumer Updates
  • Children's Health
Find US
  • Medium
  • Google Site
  • Blogspot
  • API
  • Reddit
  • Tumblr
  • Scoop.it
  • Substack
  • Wordpress
  • Wix
  • Behance

© 2025 TheMediTary.Com All rights reserved. Operated by